Non peer-reviewed data of Bharat Biotech's Covaxin showed that the vaccine possessed a total of 77.8 per cent efficiency against coronavirus in Phase 3 trials. "Efficacy against asymptomatic COVID-19 was 63.6 per cent. The vaccine conferred 65.2 per centagainst the SARS-CoV-2 Variant of Concern, B.1.617.2 [Delta]." It was 93.4 per cent effective against symptomatic COVID-19. "The vaccine was well tolerated with no clinically or statistically significant differences in the distributions of solicited, unsolicited, or serious adverse events between vaccine and placebo groups. No cases of anaphylaxis or vaccine-related deaths were reported," according to the study.
Krishna Ella, Chairman and Managing Director of Bharat Biotech, said, "The successful safety and efficacy readouts of Covaxin as a result of conducting the largest ever COVID Vaccines trials in India establishes the ability of India and developing world countries to focus towards innovation and novel product development. We are proud to state that Innovation from India will now be available to protect global populations."